Post-Marketing Safety Study on Olumiant (Baricitinib) Use Among Moderate to Severe Active Rheumatoid Arthritis Patients in China

First published 23/03/2020

Last updated 12/11/2024

EU PAS number:

EUPAS34213

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Non_interventional PASS Protocol_B021(a)

English (400.3 KB - PDF)View document

Updated protocol

Non_interventional PASS Protocol_B021_amendment (b)

First published: 22/02/2024

English (6.13 MB - PDF)View document

Study results

Study results

I4V-GH-B021(b) Non-interventional PASS final study report (3)

English (9.95 MB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents